View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
March 23, 2021updated 24 Mar 2021 8:21am

Roche to halt dosing in Huntington’s disease trial with tominersen

Roche has decided to discontinue dosing in the Phase III GENERATION HD1 study of investigational antisense therapy, tominersen, in manifest Huntington’s disease (HD).

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Clinical Trials Arena